Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 18 04:00PM ET
14.17
Dollar change
-0.29
Percentage change
-2.01
%
IndexRUT P/E- EPS (ttm)-0.79 Insider Own54.91% Shs Outstand12.85M Perf Week1.50%
Market Cap186.19M Forward P/E- EPS next Y-0.82 Insider Trans2.76% Shs Float5.93M Perf Month-0.14%
Income-10.22M PEG- EPS next Q-0.21 Inst Own8.43% Short Float7.87% Perf Quarter-11.27%
Sales0.00M P/S- EPS this Y-17.39% Inst Trans-23.11% Short Ratio9.98 Perf Half Y-16.40%
Book/sh0.45 P/B31.52 EPS next Y-1.23% ROA-112.41% Short Interest0.47M Perf Year58.32%
Cash/sh0.55 P/C25.79 EPS next 5Y- ROE-123.67% 52W Range7.58 - 21.44 Perf YTD34.70%
Dividend Est.- P/FCF- EPS past 5Y-36.91% ROI-173.92% 52W High-33.91% Beta3.31
Dividend TTM- Quick Ratio5.34 Sales past 5Y0.00% Gross Margin- 52W Low86.94% ATR (14)0.93
Dividend Ex-Date- Current Ratio5.34 EPS Y/Y TTM-14.50% Oper. Margin0.00% RSI (14)48.81 Volatility5.38% 6.56%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price38.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-59.43% Payout- Rel Volume0.36 Prev Close14.46
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsAug 12 Avg Volume46.75K Price14.17
SMA20-0.23% SMA50-3.25% SMA2004.08% Trades Volume17,090 Change-2.01%
Date Action Analyst Rating Change Price Target Change
Sep-01-21Initiated H.C. Wainwright Buy $78
Aug-01-24 06:00AM
Jun-26-24 07:33AM
Jun-17-24 09:00AM
Jun-14-24 06:00AM
May-20-24 09:53PM
10:53PM Loading…
Apr-15-24 10:53PM
Apr-10-24 03:30PM
Mar-13-24 06:00AM
Mar-12-24 06:00AM
Mar-07-24 09:00AM
Feb-27-24 06:00AM
Feb-22-24 06:00AM
Feb-14-24 06:00AM
Nov-21-23 06:00AM
Sep-13-23 05:02PM
01:12PM Loading…
Jul-26-23 01:12PM
Jul-18-23 06:53AM
May-10-23 06:32AM
May-09-23 06:40AM
May-08-23 06:41AM
May-05-23 06:58AM
May-04-23 06:29AM
May-03-23 06:46AM
May-02-23 06:46AM
May-01-23 06:45AM
Apr-28-23 07:04AM
Apr-27-23 06:47AM
Apr-26-23 06:26AM
Apr-20-23 07:03AM
Apr-19-23 06:53AM
06:54AM Loading…
Apr-17-23 06:54AM
Apr-14-23 06:37AM
Apr-13-23 06:52AM
Apr-12-23 07:07AM
Apr-11-23 06:58AM
Apr-10-23 06:44AM
Apr-07-23 07:44AM
Apr-06-23 10:37AM
07:20AM
Apr-05-23 06:11AM
Apr-04-23 07:08AM
Apr-03-23 06:48AM
Mar-31-23 06:36AM
Mar-30-23 06:36AM
Mar-29-23 06:32AM
Mar-28-23 06:46AM
Mar-24-23 06:42AM
Mar-23-23 07:01AM
Mar-21-23 06:23AM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
Feb-14-23 06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
05:30AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
06:39AM
Jan-11-23 06:53AM
Jan-05-23 05:10AM
Jan-04-23 06:54AM
Dec-29-22 06:51AM
06:48AM
Dec-28-22 06:58AM
Dec-27-22 07:11AM
Dec-23-22 06:32AM
Dec-22-22 06:34AM
Dec-21-22 09:55AM
06:46AM
Dec-01-22 06:00AM
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thompson JayeVP Clinical Reg AffairsAug 12 '24Buy13.8580011,080263,148Sep 16 06:05 AM
Patel SnehalCEO and CFOAug 06 '24Buy13.812,00027,6205,534,602Aug 08 06:05 AM
Patel SnehalCEO and CFOAug 05 '24Buy13.185,50072,4905,532,602Aug 07 06:05 AM
Thompson JayeVP Clinical Reg AffairsAug 02 '24Buy15.151,00015,150262,348Aug 05 06:05 AM
Patel SnehalCEO and CFOJul 23 '24Buy15.891,50023,8355,527,102Jul 24 06:05 AM
Thompson JayeVP Clinical Reg AffairsJul 18 '24Buy16.001,00016,000261,348Jul 22 06:05 AM
Patel SnehalCEO and CFOJun 13 '24Buy14.30174,8252,499,9985,525,602Jun 17 06:10 AM
Patel SnehalCEO and CFOApr 01 '24Buy19.083,00057,2405,350,777Apr 03 06:10 AM
Patel SnehalCEO and CFOMar 22 '24Buy19.982,50049,9505,347,777Mar 26 06:05 AM
Patel SnehalCEO and CFOMar 20 '24Buy17.681,50026,5205,345,277Mar 22 06:02 AM
Patel SnehalCEO and CFOMar 05 '24Buy12.4930,500380,9455,343,777Mar 07 06:05 AM
Patel SnehalCEO and CFOMar 04 '24Buy13.034,10053,4235,340,277Mar 06 06:05 AM
Patel SnehalCEO and CFOFeb 16 '24Buy11.1610,800120,5285,336,177Feb 21 06:05 AM
Patel SnehalCEO and CFOFeb 15 '24Buy11.0712,700140,5895,325,377Feb 20 06:04 AM
Patel SnehalCEO and CFONov 10 '23Buy10.175,00050,8385,312,677Nov 14 06:05 AM
Patel SnehalCEO and CFONov 03 '23Buy9.113,50031,8855,307,677Nov 07 06:15 AM
Thompson JayeVP Clinical Reg AffairsOct 27 '23Buy8.575004,285260,348Oct 31 06:16 AM
Patel SnehalCEO and CFOOct 26 '23Buy7.972,50019,9255,304,177Oct 30 06:15 AM
Patel SnehalCEO and CFOOct 25 '23Buy7.912,50019,7755,301,677Oct 27 06:15 AM
Patel SnehalCEO and CFOOct 10 '23Buy9.071,0009,0705,299,177Oct 12 06:05 AM
Patel SnehalCEO and CFOOct 04 '23Buy8.632,00017,2605,298,177Oct 05 06:05 AM
Thompson JayeVP Clinical Reg AffairsSep 26 '23Buy8.716005,226259,848Sep 28 06:05 AM